[go: up one dir, main page]

PE20100264A1 - Metodos para utilizar composiciones de liberacion sostenida de aminopiridina - Google Patents

Metodos para utilizar composiciones de liberacion sostenida de aminopiridina

Info

Publication number
PE20100264A1
PE20100264A1 PE2009001123A PE2009001123A PE20100264A1 PE 20100264 A1 PE20100264 A1 PE 20100264A1 PE 2009001123 A PE2009001123 A PE 2009001123A PE 2009001123 A PE2009001123 A PE 2009001123A PE 20100264 A1 PE20100264 A1 PE 20100264A1
Authority
PE
Peru
Prior art keywords
sustained
speed
methods
progressive
refers
Prior art date
Application number
PE2009001123A
Other languages
English (en)
Inventor
Andrew R Blight
Ron Cohen
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of PE20100264A1 publication Critical patent/PE20100264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION SOSTENIDA QUE COMPRENDE: A) 4-AMINOPIRIDINA EN UNA CONCENTRACION DE 10 MG; Y B) UN INMUNOMODULADOR TAL COMO INTERFERONES, NATALIZUMAB Y ACETATO DE GLATIRAMERO. SE REFIERE TAMBIEN A UN METODO DE TRATAMIENTO DE ESCLEROSIS MULTIPLE RECIDIVANTE, SECUNDARIA PROGRESIVA, PRIMARIA PROGRESIVA, PROGRESIVA-RECIDIVANTE, LA ESPASTICIDAD ASOCIADA CON ESCLEROSIS MULTIPLE, MEJORAR LA VELOCIDAD DE MARCHA Y EL TONO MUSCULAR, EN DONDE DICHO TRATAMIENTO COMPRENDE ADMINISTRAR LA COMPOSICION DE 4-AMINOPIRIDINA DOS VECES POR DIA
PE2009001123A 2008-09-10 2009-09-10 Metodos para utilizar composiciones de liberacion sostenida de aminopiridina PE20100264A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10

Publications (1)

Publication Number Publication Date
PE20100264A1 true PE20100264A1 (es) 2010-04-28

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001123A PE20100264A1 (es) 2008-09-10 2009-09-10 Metodos para utilizar composiciones de liberacion sostenida de aminopiridina

Country Status (15)

Country Link
US (3) US20100061935A1 (es)
EP (1) EP2343976A4 (es)
JP (1) JP2012502103A (es)
CN (1) CN101827522A (es)
AR (1) AR073573A1 (es)
AU (1) AU2009291781A1 (es)
BR (1) BRPI0903914A2 (es)
CA (1) CA2736381A1 (es)
CL (1) CL2009001841A1 (es)
PA (1) PA8841801A1 (es)
PE (1) PE20100264A1 (es)
RU (1) RU2011113762A (es)
TW (1) TW201010703A (es)
UY (1) UY32109A (es)
WO (1) WO2010030755A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
CA2864340A1 (en) * 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
EP3506921B1 (en) 2016-08-31 2023-05-17 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (es) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
EP1651169A4 (en) * 2003-08-01 2008-02-27 Medarex Inc POLYTHERAPIES FOR MULTIPLE SCLEROSIS
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
CA2623955C (en) * 2005-09-23 2019-12-17 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment

Also Published As

Publication number Publication date
WO2010030755A1 (en) 2010-03-18
BRPI0903914A2 (pt) 2015-07-21
EP2343976A1 (en) 2011-07-20
CL2009001841A1 (es) 2011-02-18
CA2736381A1 (en) 2010-03-18
JP2012502103A (ja) 2012-01-26
US20130330277A1 (en) 2013-12-12
AU2009291781A1 (en) 2010-03-18
US20130072527A1 (en) 2013-03-21
PA8841801A1 (es) 2010-06-28
RU2011113762A (ru) 2012-10-20
CN101827522A (zh) 2010-09-08
AR073573A1 (es) 2010-11-17
TW201010703A (en) 2010-03-16
EP2343976A4 (en) 2011-12-14
UY32109A (es) 2010-04-30
US20100061935A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
PE20100264A1 (es) Metodos para utilizar composiciones de liberacion sostenida de aminopiridina
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX369784B (es) Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
CY1113449T1 (el) Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη
EA201791850A1 (ru) Борсодержащие малые молекулы
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
TW200744568A (en) Epinephrine dosing regimens
PE20130496A1 (es) Tratamiento de artritis por lupus usando laquinimod
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
BRPI0509184A (pt) composições farmacêuticas
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
PH12013502075A1 (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
EA201291097A1 (ru) Финголимод в форме гранулированного расплава
EA200970816A1 (ru) Новая лекарственная форма
AU2012307257A8 (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
EA201390844A1 (ru) Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения
PA8657901A1 (es) Composicion que comprende una epotilona y metodos para producir dicha composicion
IN2013MU03428A (es)

Legal Events

Date Code Title Description
FC Refusal